- The world's leading pharmaceutical companies provided 1.12 billion treatments for NTDs, an increase of 150 million treatments from 2011. These commitments fully met the increased requests from endemic country partners and removed a key bottleneck to the successful treatment and prevention of NTDs.
- Twenty-nine countries began receiving albendazole or mebendazole to treat or prevent soil-transmitted helminthiasis, increasing treatments provided with those drugs from 46 million in 2011 to 238 million in 2012.
- The United Kingdom increased its spending on NTDs from US$24.7 million in 2011 to $42.5 million in 2012, while the U.S. Agency for International Development has steadily increased its donations over the past several years, reaching $89 million in 2012. These donors and others committed funds to support integrated programs, scale up and expand existing programs, increase funding available for disease mapping, improve program strategies through research and develop new tools.
- More than 40 countries developed multi-year integrated NTD plans, and Brazil, Burundi, Cameroon and Honduras launched their plans.
- Oman became the first previously endemic country verified as trachoma-free, with more expected later in 2013.
- Two NTD diagnostic tests received regulatory approval: the first ever lateral flow test for sleeping sickness was commercially launched in December 2012, and a new rapid diagnostic test for lymphatic filariasis will become commercially available in the first half of 2013.
Global Partners Making Progress Against Neglected Tropical Diseases, New Report And Scorecard Show
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts